Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Sciences to Present at Two Upcoming Investor Conferences in September

Business Wire September 3, 2014

European CHMP Adopts Positive Opinion for Gilead's Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

Business Wire July 25, 2014

Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic

ACCESS Newswire July 24, 2014

Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries

Business Wire July 24, 2014

Gilead Sciences Announces Second Quarter 2014 Financial Results

Business Wire July 23, 2014

U.S. Food and Drug Administration Approves Gilead's Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma

Business Wire July 23, 2014

Your Garden of Stocks...

Equities.com July 21, 2014

Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014

Business Wire July 16, 2014

Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C

Business Wire June 27, 2014

IPO Report: GlobeImmune (GBIM)

Equities.com June 26, 2014

Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17

Business Wire June 16, 2014

Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan

Business Wire June 15, 2014

Fasten Your Safety Belt Investors, There's Turbulence Ahead

Equities.com June 13, 2014

Biotech Investors Need to Focus on Catalysts

Equities.com June 11, 2014

Conatus (CNAT) Surges Amid Hepatitis C Fervor

Equities.com June 11, 2014

Prescription for Profit: Pharma-Biotech Industry Continues Mega-Billion Dollar Merger & Acquisition Binge, an Industrial Info News Alert

Marketwired June 11, 2014

Could Achillion (ACHN) be the Biggest Beneficiary of Merck's (MRK) Idenix (IDIX) Purchase?

Equities.com June 10, 2014

Achillion (ACHN) Soars After FDA OKs Resumption of Trial for Hepatitis C Drug

Equities.com June 10, 2014

Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 10

Business Wire June 9, 2014

Merck (MRK) to pay triple last closing price for Idenix Pharmaceuticals (IDIX)

Canadian Press June 9, 2014